Last edition
News about "HUTCHMED"
Hutchmed Initiates Tazverik Recall In China After Ipsen Withdraws Drug In US
Hutchmed (China) Limited has begun withdrawing the cancer therapy Tazverik (tazemetostat) from markets in mainland China, Hong Kong and Macau after its partner Ipsen decided to voluntarily remove the drug from the US market.
Hutchmed | 11/03/2026 | By Darshana
HUTCHMED Starts Global Trial of HMPL-A580 for Solid Tumours
HUTCHMED has initiated a global clinical trial of HMPL-A580, a PI3K/PIKK-EGFR ATTC candidate, in patients with solid tumours. The study marks the second clinical programme from its next-generation ATTC platform, targeting both PAM pathway and EGFR signaling to enhance therapeutic synergy.
HUTCHMED | 06/03/2026 | By News Bureau
HUTCHMED Begins Phase III Trial of Surufatinib-Camrelizumab Combo in Pancreatic Cancer
HUTCHMED has initiated the phase-III stage of its phase-II/III clinical trial in China evaluating a combination regimen of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, with the first patient dosed on 30 December, 2025.
HUTCHMED | 05/01/2026 | By News Bureau | 103
HUTCHMED Gets Priority Review in China for Fanregratinib NDA
HUTCHMED’s NDA for fanregratinib in second-line intrahepatic cholangiocarcinoma has been accepted in China with priority review status, supported by data from a phase II registration trial addressing a high-unmet-need liver cancer indication.
HUTCHMED | 02/01/2026 | By News Bureau
HUTCHMED Gains Wider NRDL Coverage and First Commercial Insurance Listing in China
Effective January 1, 2026, HUTCHMED will see expanded NRDL coverage for ELUNATE, ORPATHYS and SULANDA, while TAZVERIK has been added to China’s first National Commercial Health Insurance Innovative Drug List, marking its entry into commercial insurance coverage.
HUTCHMED | 08/12/2025 | By Dineshwori | 163
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy